Page 26 - ITPS-8-1

INNOSC Theranostics and
Pharmacological Sciences Transcriptome-based RNA sequencing

References 25 26

Year of study 2017 2012

The study used RNA-seq technology to identify a higher number of DEGs than previous microarray- based expression profiles, which can be used for biomarker testing and therapy of pancreatic cancer. The mRNA sequencing– centered approach can provide a more precise deconvolution of the transcriptional and post- transcriptional aspects of

Findings breast cancer.

RNA sequence analysis and database The TopHat2 alignment tool mapped 95.5% of the sequenced reads to the hg19 genome assembly, with the RefSeq database providing the number of components in each identified gene. The TopHat program 1.1.4 was used to align the pair- end readings. The OMIM database was used.

Transcriptome profile The transcriptome profile revealed 2736 DEGs with a false discovery rate of <0.05, including six microRNAs and 1554 upregulated and 1182 downregulated DEGs. mRNA sequencing identified 75,000 transcripts in samples, including GNB2L1, CANX, B2M, and SPARC, affecting cell motility, antiapoptosis effect, migration, and stress management, which are linked to breast cancer progres

Methodology adopted RNA-seq of all 20 samples was successfully performed using nucleotide distributions and high- quality parameters, with reading sequences being 2 × 76 bp long. Ribosomal RNA was extracted from total RNA using RiboMinus Eukaryote Kits and assembled into transcripts using Cufflinks; PCA plots were constructed and clustered using Avadis NGS software. lncRNA: Long non-coding RNA; qRT–PCR: Qua

Study pattern The surrounding benign pancreatic tissues and the matching tumor transcriptomes were examined in 10 patients who underwent PDAC surgery. The study examined the transcriptome expression patterns of HER2-positive, TNBC, and non-TNBC breast tumors using Illumina technology, resulting in 1.2 billion high-quality raw reads.

Table 1. (Continued) Condition/ disease No. Pancreatic ductal adenocarcinoma (PDAC) Breast cancer

10

Volume 8 Issue 1 (2025) S. 9 20 doi: 10.36922/itps.4449